|
Media event:
|
In the RE-LY® Trial dabigatran etexilate showed significant reduction in the risk of stroke and systemic embolism - including hemorrhagic strokes, significantly lower bleeding - including life threatening and intracranial bleeding and significant reduction in vascular mortality compared to well controlled warfarin. |
|---|---|
|
Venue:
|
Barcelona, Spain |
The RE-LY® Trial results
Background information for medical media outside the US only
Disclaimer
The content of the website has been cleared by Boehringer Ingelheim GmbH in compliance with the legal provisions applicable for German companies. Such provisions vary from country to country and can have an impact on the information we can provide to you.
Thus, please contact us directly in case further information is requested which takes into account the framework in your home country.
Contact
Disease & Product
Support Information
-
Prof. Stefan H. Hohnloser
University Hospital Frankfurt, Germany
Professor Stefan H. Hohnloser holds the position of Professor of Medicine and Cardiology at the J. W. Goethe University in Frankfurt, Germany. He is the Head of the Division of Clinical Electrophysiology.
-
Dr Stuart Connolly
Professor at McMaster University and Director of the Division of Cardiology
Dr Stuart Connolly is a clinical specialist in cardiac arrhythmia. Before becoming Director of the Division of Cardiology, he initiated and then led the Arrhythmia Service at Hamilton Health Sciences. Dr Connolly’s research contribution has been in the evaluation of Arrhythmia treatment. He has led more than two dozen large randomized controlled trials over the past 20 years.
-
Dr Sarah Jarvis
Richford Gate Medical Practice, London, United Kingdom
Sarah Jarvis is a GP, GP trainer, fellow of the Royal College of General Practitioners and Women’s Health spokesperson for the RCGP. She is a member of the advisory board of the British Journal of Cardiology and the Healthcare Committee of HEART UK.
-
Videos and Webcasts
-
Webcast on Demand
Available as from 31 August
View the webcast from the Boehringer Ingelheim press conference at the ESC 2009 in Barcelona on 30 August. In the RE-LY® Trial dabigatran etexilate showed significant reduction in the risk of stroke and systemic embolism - including hemorrhagic strokes, significantly lower bleeding - including life threatening and intracranial bleeding and significant reduction in vascular mortality compared to well controlled warfarin.
-
-
-
-
-
-
-
-
-
-
-
-
